Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program
Frontiers in Public Health · 2026
DOI: 10.3389/fpubh.2026.1833971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2026. Verfasst von Eunha Shim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, Soongsil University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Immunization Programs, Adjuvants, Vaccine. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
Seasonal influenza causes substantial morbidity and mortality among older adults in South Korea despite high vaccination coverage. The MF59-adjuvanted trivalent influenza vaccine (aTIV) has shown superior immunogenicity in older populations, but its economic value within the Korean National Immunization Program (NIP) has not been evaluated using a dynamic transmission model that captures indirect protection. This study evaluated the budget impact of introducing aTIV into the Korean NIP for adults aged ≥65 years.
Methods
We developed an age-structured dynamic compartmental model to simulate seasonal influenza transmission in South Korea, allowing estimation of both direct and indirect protection effects. From the healthcare payer perspective and over a single influenza season, we performed a budget impact analysis complemented by a cost–benefit comparison of avoided medical costs against incremental vaccination expenditures. Two aTIV strategies were compared against standard quadrivalent influenza vaccine (QIV) within the NIP framework: Strategy I (aTIV for adults aged ≥75 years) and Strategy II (aTIV for all adults aged ≥65 years). Deterministic one-way sensitivity analyses examined relative vaccine effectiveness (rVE) of aTIV versus QIV across 5–30% and seasonal attack rate across ±20% of the 8.0% baseline, and a break-even analysis identified the rVE threshold at which incremental costs equal avoided treatment costs. A probabilistic sensitivity analysis was also conducted to quantify joint parameter uncertainty.
Results
At baseline (rVE 25%, attack rate 8.0%), Strategy I required $24.6 million in additional vaccine investment, with 52% offset by treatment savings, yielding a net budget impact of $11.7 million (+0.9% of total influenza-related healthcare expenditure). Strategy II required $54.4 million in additional costs with 57% offset ($31.2 million in savings), resulting in a net impact of $23.2 million (+1.8%). Strategy II prevented 535 deaths and over 15,000 hospitalizations—2.2-fold greater than Strategy I. The incremental cost of aTIV decreased with increasing transmission intensity, approaching cost neutrality during severe epidemic seasons. The break-even rVE at which aTIV becomes cost-saving was 44%, above central meta-analytic estimates (10–25%) but potentially attainable in severe seasons or specific subpopulations.
Conclusion
Introduction of aTIV into the Korean NIP is budget-feasible with substantial health benefits, requiring only a 0.9–1.8% increase in total influenza-related healthcare expenditure. At current rVE estimates (≤30%), aTIV does not achieve cost savings, but the additional fiscal burden remains modest. Strategy II offers superior health outcome value and is preferred when budget permits, while Strategy I provides a fiscally conservative entry point. The value proposition of aTIV is most favorable during severe influenza seasons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mathematics, Soongsil University, Seoul, Republic of Korea.
- Department of Pediatrics, Nowon Eulji University Hospital, Seoul, Republic of Korea.
- Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.
Zitieren
APA
Shim, E., Eun, B. W., & Choi, W. S. (2026). Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2026.1833971
Vancouver
Shim E, Eun BW, Choi WS. Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program. Frontiers in Public Health. 2026. doi:10.3389/fpubh.2026.1833971
BibTeX
@article{Shim2026,
author = {Shim, Eunha and Eun, Byung Wook and Choi, Won Suk},
title = {Economic analysis of adjuvanted trivalent influenza vaccine for older adults in the Korean National Immunization Program},
journal = {Frontiers in Public Health},
year = {2026},
doi = {10.3389/fpubh.2026.1833971}
}
EUVIMED